<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051778</url>
  </required_header>
  <id_info>
    <org_study_id>Aps/UFH/enox40</org_study_id>
    <nct_id>NCT01051778</nct_id>
  </id_info>
  <brief_title>Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome</brief_title>
  <official_title>Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ahmed Elgazzar Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy and safety of Low molecular weight heparin
      (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with
      recurrent pregnancy loss associated with antiphospholipid syndrome (APS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with antiphospholipid syndrome (APS) have live birth rates as low as 10% in pregnancies
      without pharmacological treatment. Low dose aspirin (LDA) ,unfractionated heparin(UFH) , Low
      molecular weight heparin (LMWH) , prednisone, and intravenous immunoglobulin (IVIG) have been
      used either alone or in combination in order to improve the live birth rate in APS positive
      women with recurrent miscarriage. A Cochrane review of 13 randomized or quasi-randomized,
      controlled trials of various management options of pregnant women with a history of pregnancy
      loss and APL, revealed that combined UFH and aspirin was the treatment of choice which
      reduced pregnancy loss by 54% .

      During the past decade , low molecular weight heparins were widely used in the prophylaxis
      and treatment of patients with venous or arterial thrombosis ,with an efficacy and safety
      superior or at least equivalent to that of UFH .Although recent studies reported the use of
      LMWH in the management of patients recurrent pregnancy loss secondary to antiphospholipid
      syndrome resulted in encouraging results . It is not clear whether the efficacy and safety of
      LMWH is equivalent to that of UFH .

      Although LMWH is more expensive than UFH . LMWH has longer half life , greater
      bioavailability , more stable dose-response relationship than UFH and therefore can be
      administered once daily. Furthermore, LMWH requires less frequent monitoring than UFH and and
      has less adverse effect on bone mineral density and platelet count .These advantages make
      LMWH more attractive for the patients and physicians than UFH .

      There are only two studies which compared the efficacy of LMWH plus LDA with that of UFH plus
      LDA in the management of pregnant women with recurrent pregnancy loss secondary to APS. In
      addition ,no randomized controlled study has yet compared the efficacy of LMWH plus LDA with
      UFH plus LDA.

      The aim of this study is to compare the efficacy and safety of Low molecular weight heparin
      (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with
      recurrent pregnancy loss associated with antiphospholipid syndrome (APS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)</measure>
    <time_frame>pregnancy &gt; 24weeks gestation</time_frame>
    <description>Live birth occurs when a fetus (&gt; 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minor and Major Bleeding</measure>
    <time_frame>Duration of pregnancy and puerperium</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>Duration of pregnancy and puerperium</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>Pregnancy &gt; 20 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IUFD</measure>
    <time_frame>Pregnancy &gt;24 weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm Delivery</measure>
    <time_frame>24 weeks gestation&lt;Pregnancy &lt;37weeks gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous Osteoporotic Fractures</measure>
    <time_frame>Duration of pregnancy and puerperium</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Recurrent Abortion</condition>
  <arm_group>
    <arm_group_label>enoxaparin 40 mg plus low dose aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin calcium 5,000 U twice daily plus low dose aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin 40mg plus low dose aspirin</intervention_name>
    <description>Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.</description>
    <arm_group_label>enoxaparin 40 mg plus low dose aspirin</arm_group_label>
    <other_name>Clexane 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin calcium5,000 U twice daily plus low dose aspirin</intervention_name>
    <description>Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .</description>
    <arm_group_label>Heparin calcium 5,000 U twice daily plus low dose aspirin</arm_group_label>
    <other_name>Cal-Heparine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a minimum of three consecutive pregnancy losses before 10 weeks
             gestation

          -  Positive lupus anticoagulant and/or anticardiolipin antibodies (IgG and IgM) on at
             least two occasions twelve weeks apart .

          -  Age between 19 - 37 years,

          -  Body mass index between 19-30

        Exclusion Criteria:

          -  Parental chromosomal abnormalities

          -  Uterine abnormalities

          -  Luteal phase defect

          -  Systemic lupus erythematosus

          -  Previous thromboembolism

          -  Sensitivity to aspirin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usama M Fouda</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of obstetrics and Gynecology , Cairo university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed M Sayed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor of obstetrics and Gynecology , Cairo university.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahmed Elgazzar hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairo university hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005 Mar;83(3):684-90.</citation>
    <PMID>15749498</PMID>
  </reference>
  <reference>
    <citation>Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, Ensom MH. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004 Aug;26(8):729-34.</citation>
    <PMID>15307977</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>May 10, 2010</results_first_submitted>
  <results_first_submitted_qc>July 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2011</results_first_posted>
  <last_update_submitted>July 29, 2011</last_update_submitted>
  <last_update_submitted_qc>July 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Usama M. Fouda, Ahmed M .Sayed</name_title>
    <organization>Cairo university</organization>
  </responsible_party>
  <keyword>Recurrent abortion</keyword>
  <keyword>Antiphospholipid syndrome</keyword>
  <keyword>unfractionated heparin</keyword>
  <keyword>Low Molecular Weight Heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted between June 2006 to December 2009 at Cairo university hospital and Ahmed Elgazzar hospital ,Cairo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Enoxaparin 40 mg /Day Plus Low Dose Aspirin</title>
        </group>
        <group group_id="P2">
          <title>Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30">June 2006</participants>
                <participants group_id="P2" count="30">June 2006</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30">November 2009</participants>
                <participants group_id="P2" count="30">November 2009</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enoxaparin 40 mg /Day Plus Low Dose Aspirin</title>
        </group>
        <group group_id="B2">
          <title>Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.47" spread="3.20"/>
                    <measurement group_id="B2" value="28.57" spread="3.48"/>
                    <measurement group_id="B3" value="28.016" spread="3.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)</title>
        <description>Live birth occurs when a fetus (&gt; 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord.</description>
        <time_frame>pregnancy &gt; 24weeks gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enoxaparin 40 mg /Day Plus Low Dose Aspirin</title>
          </group>
          <group group_id="O2">
            <title>Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin</title>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)</title>
          <description>Live birth occurs when a fetus (&gt; 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord.</description>
          <units>Percentage of pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minor and Major Bleeding</title>
        <time_frame>Duration of pregnancy and puerperium</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thrombocytopenia</title>
        <time_frame>Duration of pregnancy and puerperium</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preeclampsia</title>
        <time_frame>Pregnancy &gt; 20 weeks gestation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IUFD</title>
        <time_frame>Pregnancy &gt;24 weeks gestation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Preterm Delivery</title>
        <time_frame>24 weeks gestation&lt;Pregnancy &lt;37weeks gestation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spontaneous Osteoporotic Fractures</title>
        <time_frame>Duration of pregnancy and puerperium</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>June 2006 to December 2009</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Enoxaparin 40 mg /Day Plus Low Dose Aspirin</title>
        </group>
        <group group_id="E2">
          <title>Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Severe bleeding episodes , e.g antepartum hemorrhage or postpartum hemorrhage</sub_title>
                <counts group_id="E1" events="30" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="30" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Usama .M .Fouda</name_or_title>
      <organization>Cairo university</organization>
      <phone>+20123595106</phone>
      <email>umfrfouda@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

